A new PDUFA target date is April 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for STS101 (dihydroergotamine [DHE] nasal ...

A recent study at Kansas State University – presented at the American Association of Bovine Practitioners Conference in Columbus, Ohio -- demonstrated how lidocaine-infused castration bands can help ...

STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma's proprietary nasal delivery device.

Peppermint is a natural alternative therapy that's used to treat a variety of health issues, including headaches, hair loss, ...

This blog contains affiliate links, and I may earn a small commission from qualifying purchases at no extra cost to you. Migraines have been plaguing my life for almost twenty years now. I’ve had ...

The following is a summary of “Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis,” published in the November 2024 issue of Allergy and Immunology by ...

Summary: Nebulization is gaining popularity as a treatment alternative, and many drugs are used unlabeled in a nebulized form, including the opioids, lidocaine, magnesium sulfate, amphotericin B ...

(SNBL), is a late-stage biopharmaceutical company that is currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101, a novel, investigational therapeutic product for ...

Am J Health Syst Pharm. 2006;63(18):1704-1716. A case study by Wu et al. [23] reported lidocaine toxicity in a 48-kg woman with multiple health conditions receiving nebulized lidocaine before ...